Martin Roatsch - Concepedia

Author

Martin Roatsch

University of Freiburg ORCID

Also Known As

M. Roatsch, Martin Roatsch, Roatsch, Martin

Publications

565

Citations

H-Index

Concepts

All Affiliations

University of Freiburg Leipzig University University Medical Center Freiburg University of Copenhagen Vanderbilt University

About

Martin Roatsch is an author at University of Freiburg specializing in natural sciences, quantum chemistry, and physical chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	5	5	243
2	Engineering	3	3	203
3	Medicine	2	2	40
4	Biochemistry	2	2	40
5	Applied Physics	1	1	35

Martin Roatsch

Publications

441

Citations

H-Index

Page 1

	Year	Citations
On the physical origin of the cation–anion intermediate bond in ionic liquids Part I. Placing a (weak) hydrogen bond between two charges Sebastian B. C. Lehmann, Martin Roatsch, Matthias Schöppke, Physical Chemistry Chemical Physics EngineeringIonic Liquids PartComputational ChemistryPhysical OriginChemistry	2010	127
Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs) Laura Sinatra, Jan J. Bandolik, Martin Roatsch, Angewandte Chemie International Edition	2020	69
Coupled Cluster in Condensed Phase. Part I: Static Quantum Chemical Calculations of Hydrogen Fluoride Clusters Joachim Friedrich, Eva Perlt, Martin Roatsch, Journal of Chemical Theory and Computation EngineeringComputational ChemistryChemistryHydrogen Fluoride DimerBiophysics	2011	41
Coupled Cluster in Condensed Phase. Part II: Liquid Hydrogen Fluoride from Quantum Cluster Equilibrium Theory Christian Spickermann, Eva Perlt, Michael von Domaros, Journal of Chemical Theory and Computation Quantum LiquidEngineeringComputational ChemistryChemistryLiquid Hydrogen Fluoride	2011	35
Tetrazolylhydrazides as Selective Fragment‐Like Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A Nicole Rüger, Martin Roatsch, Thomas Emmrich, ChemMedChem	2015	33
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases Martin Roatsch, Inga Hoffmann, Martine I. Abboud, ACS Chemical Biology	2019	30
Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells Christian Lis, Stefan Rubner, Martin Roatsch, Scientific Reports ApoptosisCell DeathSignaling PathwayStat3-dependent MannerReceptor Tyrosine Kinase	2017	26
Substituted 2-(2-Aminopyrimidin-4-Yl)Pyridine-4-Carboxylates as Potent Inhibitors of Jumonjic Domain-Containing Histone Demethylases Martin Roatsch, Dina Robaa, Martin Pippel, Future Medicinal Chemistry	2016	19
Structure‐Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases Nicole Rüger, Martin Roatsch, Oxana Krylova, ChemMedChem	2019	19
4‐Biphenylalanine‐ and 3‐Phenyltyrosine‐Derived Hydroxamic Acids as Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A Ludovica Morera, Martin Roatsch, Michael C. D. Fürst, ChemMedChem	2016	18

Page 1